An update on primary findings and new designs in biotherapy studies for acute myocardial infarction.

Abstract

Treatment of acute myocardial infarction in the future should focus not only on improving acute treatment, as it has been done over the past decades, but also on secondary prevention of left ventricular dysfunction and/or progression to heart failure by preserving left ventricular shape, avoiding left ventricular remodeling and stimulating cardiac regeneration. Biotherapies with adult stem cells and bone marrow-derived endothelial cell progenitors, combined or not with biomaterials, and new drugs are under investigation and will probably be part of routine clinical practice for patients suffering from myocardial infarction in the near future.

• Authors: Jerome Roncalli
• Journal: Future cardiology (Future Cardiol) Vol. 10 Issue 6 Pg. 781-8 (Nov 2014) ISSN: 1744-8298 [Electronic] England
• PMID: 25495819 (Publication Type: Journal Article, Review)

Topics

• Biological Therapy (methods)
• Heart Failure (etiology, prevention & control)
• Humans
• Myocardial Infarction (complications, therapy)
• Ventricular Dysfunction, Left (etiology, prevention & control)
• Ventricular Remodeling